ATE515574T1 - Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen - Google Patents

Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen

Info

Publication number
ATE515574T1
ATE515574T1 AT07804686T AT07804686T ATE515574T1 AT E515574 T1 ATE515574 T1 AT E515574T1 AT 07804686 T AT07804686 T AT 07804686T AT 07804686 T AT07804686 T AT 07804686T AT E515574 T1 ATE515574 T1 AT E515574T1
Authority
AT
Austria
Prior art keywords
determining
odds ratio
spla2 activity
value
risk
Prior art date
Application number
AT07804686T
Other languages
English (en)
Inventor
Alain Tedgui
Ziad Mallat
Joelle Benessiano
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE515574T1 publication Critical patent/ATE515574T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
AT07804686T 2006-07-31 2007-07-31 Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen ATE515574T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291238A EP1884571A1 (de) 2006-07-31 2006-07-31 Verwendung von spla2 aktivität zur diagnose von Herz und Kreislaufskrankheiten
PCT/IB2007/002211 WO2008015546A1 (en) 2006-07-31 2007-07-31 Use of spla2 activity for the diagnosis of a cardiovascular event

Publications (1)

Publication Number Publication Date
ATE515574T1 true ATE515574T1 (de) 2011-07-15

Family

ID=37085751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07804686T ATE515574T1 (de) 2006-07-31 2007-07-31 Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen

Country Status (8)

Country Link
US (1) US8187818B2 (de)
EP (3) EP1884571A1 (de)
JP (1) JP5484050B2 (de)
AT (1) ATE515574T1 (de)
CA (1) CA2659428A1 (de)
ES (1) ES2367200T3 (de)
PL (1) PL2046977T3 (de)
WO (1) WO2008015546A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038104A1 (en) 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
US8349577B2 (en) 2009-04-23 2013-01-08 Research Foundation For Mental Hygiene, Inc. Method for evaluating blood-neural barrier permeability
WO2011020906A2 (en) 2009-08-21 2011-02-24 INSERM (Institut National de la Santé et de la Recherche Médicale) sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
WO2011039578A1 (en) * 2009-10-02 2011-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
WO2012170396A1 (en) * 2011-06-07 2012-12-13 Philadelphia Health & Education Corporation Spla2 monitoring strip

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003069305A2 (en) * 2002-02-13 2003-08-21 Wisconsin Alumni Research Foundation Fluorescent phospholipase assay, phospholipase a2 inhibitor and stimulator, and the use thereof
WO2006121852A2 (en) * 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
AU2007223903B2 (en) * 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ATE551071T1 (de) * 2006-09-08 2012-04-15 Medimmune Llc Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen

Also Published As

Publication number Publication date
EP2046977A1 (de) 2009-04-15
US8187818B2 (en) 2012-05-29
EP2360268A1 (de) 2011-08-24
ES2367200T3 (es) 2011-10-31
EP1884571A1 (de) 2008-02-06
JP2009545306A (ja) 2009-12-24
CA2659428A1 (en) 2008-02-07
JP5484050B2 (ja) 2014-05-07
EP2046977B1 (de) 2011-07-06
WO2008015546A1 (en) 2008-02-07
US20090325194A1 (en) 2009-12-31
PL2046977T3 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
ATE515574T1 (de) Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen
ATE491953T1 (de) Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
DE60314042D1 (de) Vorrichtungen und Methoden zur Bestimmung von Konzentrationen von Analyten
WO2008040998A3 (en) Systems and methods for determining a substantially hematocrit independent analyte concentration
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
DE60336177D1 (de) Auswertungsverfahren von Amplitudenwerten zur Ermittlung eines Slice-Level-Werts
DE602006010195D1 (de) Verfahren und system zur bestimmung mehrerer lastkomponenten an einem rad
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
RU2008103988A (ru) Способ диагностики рассеяного склероза
WO2008090319A3 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
DE602006014798D1 (de) Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten
ATE482394T1 (de) Verfahren, vorrichtung und programm zur bewertung der immunität sowie datenaufzeichnungsmedium mit darin gespeichertem immunitätsbewertungsprogramm
ATE524561T1 (de) Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE60021369D1 (de) Verfahren zur abschätzung eines magengeschwür-risikos
DE602004004775D1 (de) Verfahren zur Diagnose von Leberfibrose.
CA2575405A1 (en) Method for diagnosing liver fibrosis
ATE532073T1 (de) Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
WO2012175183A4 (en) Determination of direct thrombin inhibitors in fluids like serum or urine
DE602004020372D1 (de) Verfahren zur probenvorbehandlung sowie immunologisches testverfahren unter verwendung davon
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
ATE467130T1 (de) Verwendung von xcri zur diagnose oder überwachung von immuntoleranz
WO2010027260A3 (en) Biomarkers for identifying subjects predisposed to developing insulin resistance and determining the insulin resistance status

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties